Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CBP501 |
Trade Name | |
Synonyms | CBP-501|CBP 501 |
Drug Descriptions |
CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764). |
DrugClasses | CHK1 Inhibitor 18 |
CAS Registry Number | 565434-85-7 |
NCIT ID | C71529 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bleomycin + CBP501 | Bleomycin CBP501 | 0 | 0 |
CBP501 | CBP501 | 0 | 0 |
CBP501 + Cisplatin | CBP501 Cisplatin | 0 | 1 |
CBP501 + Cisplatin + Nivolumab | CBP501 Cisplatin Nivolumab | 0 | 2 |